Table 1.
Characteristics of the patient cohort enrolled in this study
| Train | Test | |
|---|---|---|
| No. of Patients | 469 | 40 |
| Gender (Female/ Male) | 244 / 225 | 26 /14 |
| Mean Age | 61 | 62 |
| No. of Metastases | 1149 | 83 |
| Metastases < 0.4 ml (No. of Patients) | 524 (257) | 47 (24) |
| Median Lesion Size | 0.31 ml | 0.47 ml |
| IQR | (0.09–1.32 ml) | (0.14–1.82 ml) |
| Mean Lesion Size | 1.29 ml | 1.92 ml |
| Primary Tumor | ||
| Lung | 255 | 20 |
| Melanoma | 85 | 9 |
| Breast | 48 | 4 |
| Other | 66 | 6 |
| Mixed | 9 | 0 |
| CUP | 6 | 1 |
| Year of Treatment | ||
| 2013 | 13 | 1 |
| 2014 | 78 | 2 |
| 2015 | 98 | 6 |
| 2016 | 97 | 14 |
| 2017 | 97 | 8 |
| 2018 | 63 | 6 |
| 2019 | 23 | 3 |
| MR Device (Field Strength) | ||
| Ingenia (3.0 T) | 372 | 37 |
| Ingenia (1.5 T) | 2 | 0 |
| Archieva (3.0 T) | 93 | 3 |
| Intera (1.5 T) | 2 | 0 |